Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsed Inhaled Nitric Oxide in COPD-Associated Pulmonary Hypertension
NCT03135860Phase 1Terminated
- Sponsor
- Bellerophon Therapeutics
- Start
- Oct 2016
- Primary completion
- Aug 2017
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nitric oxide in pulmonary hypertension (PH), sponsored by Bellerophon Therapeutics. Primary endpoint: Change in lobar blood volume at total lung capacity at 4 weeks. Started Oct 2016; status: terminated.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03135860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135860.